A number of research firms have changed their ratings and price targets for Ironwood Pharmaceuticals (NASDAQ: IRWD):

  • 8/9/2017 – Ironwood Pharmaceuticals was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/4/2017 – Ironwood Pharmaceuticals was given a new $20.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 8/2/2017 – Ironwood Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $23.00 price target on the stock, up previously from $22.00.
  • 7/31/2017 – Ironwood Pharmaceuticals was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 7/28/2017 – Ironwood Pharmaceuticals was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 7/24/2017 – Ironwood Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/23/2017 – Ironwood Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $20.00 price target on the stock.
  • 7/23/2017 – Ironwood Pharmaceuticals had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $22.00 price target on the stock.
  • 7/22/2017 – Ironwood Pharmaceuticals was given a new $19.00 price target on by analysts at Wells Fargo & Company. They now have a “buy” rating on the stock.
  • 7/21/2017 – Ironwood Pharmaceuticals was downgraded by analysts at Wood & Company from an “overweight” rating to a “neutral” rating.
  • 7/21/2017 – Ironwood Pharmaceuticals had its “neutral” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $19.00 price target on the stock, down previously from $20.00.
  • 7/17/2017 – Ironwood Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Lower-than-expected sales of key drug Linzess due to inventory destocking hurt the top line in the first quarter. However, Linzess sales are expected to accelerate in the upcoming quarters. The company is also working on expanding the drug’s label. Investor focus should be on the stock as a number of key pipeline data read-outs/approvals are expected this year including the approval and launch of Duzallo and phase IIb data for IW-3718. Both the candidates have significant commercial potential.  Ironwood’s shares have outperformed the drugs industry so far this year. However, competition in CIC and IBS-C, Linzess’ target markets, is intensifying. Also, the uptake of Zurampic has been slow and management expects sales to be nominal in 2017. Loss estimates have been stable lately ahead of the company’s Q2 earnings release. The company has a mixed record of earnings surprises in recent quarters.”
  • 7/6/2017 – Ironwood Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/4/2017 – Ironwood Pharmaceuticals had its price target raised by analysts at Mizuho from $21.00 to $22.00. They now have a “buy” rating on the stock.
  • 6/30/2017 – Ironwood Pharmaceuticals was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 6/23/2017 – Ironwood Pharmaceuticals was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 6/16/2017 – Ironwood Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Wedbush. They now have a $13.00 price target on the stock.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) traded up 0.53% during trading on Wednesday, reaching $15.09. 1,125,022 shares of the company were exchanged. The company’s 50-day moving average price is $18.27 and its 200-day moving average price is $17.13. The stock’s market capitalization is $2.24 billion. Ironwood Pharmaceuticals, Inc. has a 1-year low of $12.48 and a 1-year high of $19.94.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last announced its earnings results on Thursday, August 3rd. The biotechnology company reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.23) by $0.05. The company had revenue of $65.10 million for the quarter, compared to analysts’ expectations of $70 million. Ironwood Pharmaceuticals had a negative return on equity of 333.83% and a negative net margin of 52.97%. The company’s quarterly revenue was up 19.7% compared to the same quarter last year. During the same period last year, the business earned ($0.16) EPS. On average, equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post ($1.03) EPS for the current year.

In other news, insider Thomas A. Mccourt sold 30,000 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $18.20, for a total value of $546,000.00. Following the completion of the transaction, the insider now owns 30,000 shares of the company’s stock, valued at $546,000. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Halley E. Gilbert sold 35,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $19.75, for a total transaction of $691,250.00. Following the completion of the transaction, the insider now directly owns 35,000 shares of the company’s stock, valued at approximately $691,250. The disclosure for this sale can be found here. Company insiders own 7.63% of the company’s stock.

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Receive News & Ratings for Ironwood Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.